Arcutis Biotherapeutics (ARQT) Stock Statistics & Valuation Metrics

Arcutis Biotherapeutics has a market cap or net worth of $3.28B. The enterprise value is $3.26B.

Arcutis Biotherapeutics has 125,083,374 shares outstanding. The number of shares has decreased by -2.65% in one year.

Arcutis Biotherapeutics’s return on equity (ROE) is -0.09 and return on invested capital (ROIC) is -4.02%.

The current PE Ratio of Arcutis Biotherapeutics is ―. Arcutis Biotherapeutics’s PEG ratio is 2.52.

In the last 12 months, Arcutis Biotherapeutics had revenue of 376.07M and earned -16.14M in profits. Earnings per share was -0.13.

In the last 12 months, operating cash flow was 26.99M and capital expenditures -78.00K, giving a free cash flow of 26.92M billion.

Arcutis Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Arcutis Biotherapeutics upcoming earnings date is Jul 30, 2026, After Close (Confirmed).

Arcutis Biotherapeutics as a current ratio of 3.17, with Debt / Equity ratio of 6.96%

In the past 12 months, Arcutis Biotherapeutics has paid 1.17M in taxes.

Arcutis Biotherapeutics EV to EBITDA ratio is 1.48K, with an EV/FCF ratio of -579.66.

Arcutis Biotherapeutics has $224.00M in cash and marketable securities with $13.20M in debt, giving a net cash position of $210.80M billion.

Gross margin is 90.94%, with operating margin of -3.25%, and net profit margin of -4.29%.

The average price target for Arcutis Biotherapeutics is $34.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy